MetLife Investment Management, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 102 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2018. The put-call ratio across all filers is 2.89 and the average weighting 1.0%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2018$55,000
-70.6%
23,421
-64.4%
0.00%
-50.0%
Q4 2017$187,00065,7500.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2018
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,000$3,096,000100.00%
TSP Capital Management Group, LLC 698,674$1,549,0000.79%
Meditor Group Ltd 6,312,700$2,847,0000.61%
Telemetry Investments, L.L.C. 186,200$84,0000.04%
GSA CAPITAL PARTNERS LLP 1,270,500$573,0000.03%
Benchmark Capital Advisors 53,400$24,0000.02%
BOENNING & SCATTERGOOD, INC. 80,150$36,0000.01%
NJ State Employees Deferred Compensation Plan 80,000$36,0000.01%
Centiva Capital, LP 121,720$55,0000.01%
Overbrook Management Corp 48,611$22,0000.00%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders